Research-only educational guide

CJC-1295 Dosage Calculator and Chart

An academic summary of CJC-1295 (a long-acting growth hormone-releasing hormone analogue), including mechanistic background, dosing structures described in published research, safety observations, and primary literature references.

Overview

CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) designed to stimulate endogenous growth hormone (GH) secretion from the anterior pituitary gland. It was developed to overcome the short plasma half-life of native GHRH.

Multiple formulations exist, including CJC-1295 with Drug Affinity Complex (DAC), CJC-1295 without DAC, and experimental combinations with ghrelin mimetics.

Mechanism of Action

  • Acts as a GHRH receptor agonist at the anterior pituitary
  • Stimulates pulsatile release of growth hormone (GH)
  • Leads to secondary increases in insulin-like growth factor-1 (IGF-1)
  • DAC formulation binds albumin, extending biological half-life

The DAC modification increases half-life from minutes to several days, allowing less frequent administration in research settings.

Reported Research Effects

Endocrine Effects

  • 2–10× increase in plasma GH levels
  • 1.5–4× increase in IGF-1 levels
  • Effects sustained for several days with DAC

Physiologic Interest

  • Body composition research models
  • Muscle and recovery physiology
  • Bone metabolism studies

Many findings originate from animal models or short-term human trials. Translational significance remains under investigation.

Safety & Side Effects

In controlled human studies, CJC-1295 DAC was generally well tolerated. Adverse effects were dose-dependent.

  • Injection site reactions
  • Headache
  • Transient hypertension
  • Gastrointestinal discomfort

Higher doses (>30 μg/kg) were associated with increased adverse events.

CJC-1295 DAC Dosing (Research Context)

Human trials evaluated weekly or bi-weekly administration at doses ranging from 30–60 μg/kg.

Body Weight Weekly Total (μg)
100–150 lb1,360–2,040
151–200 lb2,040–2,720
201–250 lb2,720–3,400

CJC-1295 No-DAC Dosing (Research Context)

No-DAC formulations resemble modified GRF(1-29) analogues and have a shorter half-life, requiring more frequent administration in experimental designs.

  • Typical reference range: 500–2000 μg daily
  • Often administered once daily before sleep
  • Studied for up to 16 weeks in related analogues

CJC-1295 / Ipamorelin Combination (Research)

Combination protocols remain experimental. Literature suggests a 1:1 ratio totaling approximately 20 μg/kg per day in research models.

Long-term safety data for combined use remains limited.

Handling & Reconstitution

  • Lyophilized peptide requiring sterile reconstitution
  • Use bacteriostatic or sterile water per protocol
  • Avoid agitation; dissolve gently
  • Refrigerated storage as required

Conclusion

CJC-1295 represents a well-studied long-acting GHRH analogue with demonstrated effects on GH and IGF-1 secretion in research contexts. Despite promising findings, its use remains confined to controlled experimental settings.

References

  1. Teichman SL et al. J Clin Endocrinol Metab. 2006.
  2. Jetté L et al. Endocrinology. 2005.
  3. Henninge J et al. Drug Test Anal. 2010.
  4. World Anti-Doping Agency. Prohibited List.